top of page
.jpg)
NEW BOOK
LATEST NEWS
Biogen's Salanersen Shows Promise for SMA Patients Post-Gene Therapy
Biogen’s experimental drug, Salanersen, is showing promising potential for treating children with spinal muscular atrophy (SMA), even...
1 day ago
Sarepta Pauses Duchenne Gene Therapy Trial After Second Patient Death
Sarepta Therapeutics has temporarily halted its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys, after a second patient died...
1 day ago
Eli Lilly Acquires Verve Therapeutics to Enhance Cardiovascular Portfolio
Eli Lilly has acquired gene-editing startup Verve Therapeutics for approximately $1 billion, expanding its portfolio to include...
1 day ago
GENE TECH TIMES
The Future Has Arrived
Penn Medicine Studies on AAV-based Gene Therapies Suggest Integration into Human DNA is Unlikely to Drive Cancer Mutations
Penn Medicine research offers promising insights into AAV-based gene therapies' safety: Integration into human DNA is unlikely to trigger...
Mar 1, 2024
bottom of page